LOGO
LOGO

Email This Article

Theriva Q1 Net Loss Narrows; Plans Dosing Feasibility Study Of VCN-01 In H2,2026;Stock Down
To Email: *
Bcc: Seperate multiple addresses with commas(,)
Your Email: *
Format :

* Denotes Required Fields